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E-mail address: tak-yokota.nuro@tmd.ac.jp (T. YokIn short hairpin RNA (shRNA) transgenic mice, the tissue difference in gene silencing efﬁciency and
oversaturation of microRNA (miRNA) pathway have not been well assessed. We studied these prob-
lems in our previously-reported anti-copper/zinc superoxide dismutase (SOD1) shRNA transgenic
mice. Although there was a tissue difference (liver and skeletal muscle, >95%; central nervous sys-
tem and lung, 80%), the target gene silencing was systemic and our anti-SOD1 shRNA transgenic
mice recapitulated the SOD1-null mice. Neither endogenous miRNAs nor their target gene levels
were altered, indicating the preservation of endogenous miRNA pathways. We think that the shRNA
transgenic mice can be utilized for gene analysis.
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
RNA interference (RNAi) is evolutionally conserved sequence-
speciﬁc post-transcriptional gene silencing, which is mediated by
small double stranded RNA (dsRNA) [1]. The long dsRNA is cleaved
by an RNase III enzyme, Dicer, in cytoplasm to generate small
interfering RNA (siRNA) that is 21–23 base pair dsRNA. The target
mRNA is recognized by guide (antisense) strand of the dsRNA in
RNA-induced silencing complex (RISC), and is cleaved by Argona-
ute-2 (Ago2) protein, one of the main components of RISC [2]. This
post-transcriptional gene silencing can be effectively induced by
exogenously introduced siRNA or intracellularly expressed short
hairpin RNA (shRNA) in mammalian cells [2,3].chemical Societies. Published by E
NA, microRNA; RNAi, RNA
-induced silencing complex;
utase; Pol III, polymerase III;
SDS, sodium dodecyl sulfate;
scription polymerase chain
ydrogenase; snRNA, small
ota).The shRNA transgenic mice have been published [4–7] and ex-
pected to be an alternative method to the conventional knockout
mice. For using shRNA transgenic mice as a tool for gene analysis
in vivo, we need to know difference in silencing efﬁciency among
tissues. Moreover, in shRNA transgenic mice, it is also important
to elucidate whether microRNA (miRNA) is normally processed,
because shRNA and miRNA share intracellular machineries for
their maturation in mammalian cells [8–10]. We had generated
anti-mouse copper/zinc superoxide dismutase (SOD1) shRNA
transgenic mice, in which shRNA was ubiquitously expressed by
the RNA polymerase III (Pol III) promoter [11]. Using these mice,
we here evaluated the silencing efﬁciency in various tissues and
studied endogenous miRNA pathway.2. Materials and methods
2.1. Generation of anti-SOD1 shRNA transgenic mice
All experiments were approved by the Animal Experiment Com-
mittees of Tokyo Medical and Dental University (#0090104) and
Kinki University (KAAT-19-006). We generated an anti-SOD1lsevier B.V. All rights reserved.
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reported previously [11,12]. In brief, we inserted anti-SOD1 shRNA
driven by human U6 promoter into pUC19 (Takara). The shRNA
expression vector was introduced into the 129/Sv embryonic stem
(ES) cells (Chemicon) by electroporation. The ES cell clones in
which SOD1 protein levels were effectively suppressed were intro-
duced into C57BL/6 blastocysts (CLEA) by microinjection. We ob-
tained F1 transgenic mice by crossing the chimeric male mice
with wild-type C57BL/6 female mice.
2.2. Histological study
To analyze hepatic lipid accumulation, liver samples from
8-month-old shRNA transgenic male mice and wild-type litter-
mates were sectioned (4 lm) and ﬁxed in 4% paraformaldehyde/
phosphate-buffered saline (PBS) for 5 min, and then stained with
ﬁltrated Sudan III (Muto pure chemicals) at 37 C for 30 min.
Counterstaining of nuclei was performed with Mayer hematoxylin
solution (Muto pure chemicals) for 3 min.
2.3. Western blot analysis
Western blot analysis was performed as reported previously
[11]. Mice were killed under anesthesia with pentobarbital sodium,
and perfused with cold PBS. Tissues were homogenized in the cold
buffer containing 0.1% sodium dodecyl sulfate (SDS), 1% sodium
deoxycholate, 1% Triton X-100, 1 mM phenylmethylsulfonyl ﬂuo-
ride and protease inhibitor cocktail (Sigma). Equal amounts of pro-
tein from each sample were loaded in the assays. The separated
proteins were detected by speciﬁc primary antibodies; rabbit
anti-SOD1 antibody (1:5000, StressGen Biotechnologies), mouse
anti-b-tubulin antibody (1:1000, BD Biosciences), mouse anti-Actin
antibody (1:1000, Santa Cruz Biotechnology), mouse anti-Ago2
antibody (1:500, Abcam), or rabbit anti-N-ras antibody (1:500,
Santa Cruz Biotechnology).
2.4. Northern blot analysis
Northern blot analysis was performed as reported previously
[11]. Ten micrograms of total RNA from each sample were loaded
in the assays. The DNA probes which were used to detect RNAs
were as follows; complementary DNA (cDNA) (bases 15–495) for
mouse SOD1; cDNA (bases 300–614) for mouse glyceraldehyde-
3-phosphate dehydrogenase (GAPDH); 50-GGTGGAAATGAAGAAA-
GTAC-30 for anti-SOD1 siRNA guide strand; 50-ACTATACAACCTAC-
TACCTCA-30 for mouse let-7a; 50-GGCATTCACCGCGTGCCTTA-30
for mouse miR-124a; 50-AAATATGGAACGCTTCACGA-30 for mouse
U6 small nuclear RNA (snRNA).
2.5. Quantitative reverse transcription polymerase chain reaction
(RT-PCR)
After treating with TURBO DNA-free (Ambion) to remove
residual genomic DNA, 1 lg of total RNA from each sample was
reversely transcribed to cDNA using SuperScript III Reverse
Transcriptase (Invitrogen). The cDNA was used for quantitative
PCR with TaqMan system using the ABI Prism 7700 Sequence
Detection System (Applied Biosystems) according to the manufac-
turer’s protocol. The primers and probe used to quantify mouse
SOD1 were 50-GGTGCAGGGAACCATCCA-30 for forward primer, 50-
CCCATGCTGGCCTTCAGT-30 for reverse primer, and 50-AGGCA-
AGCGGTGAACCAGTTGTGTTG-30 for probe. The primer and probe
sets of mouse GAPDH, N-ras and N-myc were purchased from
Applied Biosystems. GAPDH was used to normalize the quantita-
tive RT-PCR values.2.6. Laser microdissection and RNA extraction frommotor neurons and
non-neuronal cells
Collection of motor neurons and non-neuronal cells was per-
formed as reported previously [13]. Spinal cords of the transgenic
mice or wild-type littermates were removed and embedded in Tis-
sue-Tek O.C.T. Compound (Sakura Finetek). Seven micrometer
thick sections were mounted on a MembraneSlide (Leica) and
stained with HistoGene staining solution (Arcturus). Approximate
one thousand motor neurons and neighboring non-neuronal cells
were dissected from the ventral horn of the lumbar spinal cord
for each mouse using an AS LMD system (Leica). Total RNA was ex-
tracted using RNeasy Micro Kit (Qiagen) according to the manufac-
turer’s protocol.
2.7. Subcellular fractionation
Subcellular fractionation was performed as described previ-
ously [14]. The cerebrum or liver was gently homogenized in cold
buffer (0.22 M D-mannitol, 0.07 M sucrose, at 1 mg tissue/10 ll
buffer) with a glass-Teﬂon homogenizer (30 up-and-down
strokes), and centrifuged at 600g for 10 min. The pellets were
suspended with 2.2 M sucrose and centrifuged at 40000g for
1 h. The resulting pellets were used as nuclear fraction. The super-
natants generated by the ﬁrst centrifugation were used as cyto-
plasmic fraction. Total RNA was extracted using ISOGEN (Nippon
Gene) for nuclear fraction and ISOGEN-LS (Nippon Gene) for cyto-
plasmic fraction, respectively.
2.8. Statistical analysis
Student’s t-test was used to evaluate difference among tissues
or difference between transgenic mice and wild-type littermates.
Signiﬁcance was set at P < 0.05. To compare the expression level
on Western blot or Northern blot analysis, we used NIH ImageJ
to quantify the band intensity.3. Results
3.1. Anti-SOD1 shRNA transgenic mice recapitulate SOD1-null mice
As reported previously, we obtained anti-SOD1 shRNA trans-
genic mice (Fig. 1A) [11]. The silencing effect of the target gene
was signiﬁcant on both RNA and protein levels, and was stable
with age and through to the F3 generation [11]. In contrast, there
was no change in the expression levels of unrelated genes includ-
ing GAPDH and b-actin (P = 0.75 and 0.27, respectively, data not
shown). The transgenic mice showed no remarkable phenotype
during development. The adult mice exhibited mild fatty liver
(Fig. 1B and C) and female infertility (data not shown), which were
also observed in SOD1-null mice [15,16]. These ﬁndings indicate
that the phenotype of the anti-SOD1 shRNA transgenic mice is sim-
ilar to that of SOD1-null mice.
3.2. The siRNA-silencing efﬁciency differs among the tissues of the
shRNA transgenic mice
We analyzed the siRNA-silencing efﬁciency in the various tis-
sues of the shRNA transgenic mice. On Western blot analysis, we
observed marked suppression of SOD1 protein in all the tissues
examined (Fig. 2A). However, the siRNA-silencing efﬁciency was
clearly different among the tissues; it was extremely high in the li-
ver and skeletal muscle (>95%) and, in contrast, was relatively low
in the central nervous system and lung (80%) (Fig. 2A and B). The
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Fig. 1. Generation of anti-SOD1 shRNA transgenic mice. (A) Western blot analysis of SOD1 (upper) and b-tubulin (middle), and genomic PCR of transgene (lower) in the tails.
Histological analysis in the liver of the wild-type littermates (B) and shRNA transgenic mice (C). The sections were stained with Sudan III. WT, age-matched wild-type
littermates; TG, transgenic mice.
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Fig. 2. Silencing efﬁciency in the various tissues of the shRNA transgenic mice. (A) SOD1 protein levels on Western blot analysis in the tissues of the transgenic mice. A half
amounts of the wild-type samples are loaded in the middle lanes of left panel to show that the signals are not saturated. (B) Quantiﬁcation of their band intensities. Values are
the ratio to those of age-matched wild-type littermates (mean and S.D., n = 3, *P < 0.05; signiﬁcance compared to cerebrum). (C) SOD1 mRNA of the cerebrum, liver and
skeletal muscle on Northern blot analysis. (D) Quantitative RT-PCR of SOD1 mRNA in the cerebrum and liver. Values are the ratio to age-matched wild-type littermates (mean
and S.D., n = 3, *P < 0.05; signiﬁcance compared to cerebrum).
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ysis (Fig. 2C) and quantitative RT-PCR (Fig. 2D).
3.3. The siRNA-silencing efﬁciency in neuronal cells is relatively lower
than those in hepatocytes and muscle ﬁbers
Because central nervous system is composed of heterogenous
cell populations, we sought to evaluate the siRNA-silencing efﬁ-ciency in neuronal and non-neuronal cells using laser microdissec-
tion method. The motor neurons and non-neuronal cells were
isolated from the ventral horn of the lumbar spinal cords in the
shRNA transgenic mice or wild-type littermates (Fig. 3A–D), and
SOD1 mRNA levels were quantiﬁed by quantitative RT-PCR. The
silencing efﬁciency in the motor neurons was approximately 80%
which was similar to the non-neuronal cells (Fig. 3E) and the whole
spinal cord tissue (Fig. 2B), and was less than those in the liver and
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Fig. 3. Silencing efﬁciency in the neuronal and non-neuronal cells of the shRNA transgenic mice. (A–D) Microdissection of motor neurons and non-neuronal cells in the
ventral horn of the lumbar spinal cord of the transgenic mice and age-matched wild-type littermates. Motor neurons (A and B) and non-neuronal cells (C and D) were
dissected by laser microbeam. (E) Quantiﬁcation of SOD1 mRNA in the motor neurons and non-neuronal cells by quantitative RT-PCR (mean and S.D., n = 3).
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composed of hepatocytes and muscle ﬁbers, respectively, these re-
sults indicate that the siRNA-silencing efﬁciency is different among
cell populations in the shRNA transgenic mice.
3.4. The mechanism of tissue difference in siRNA-silencing efﬁciency
In order to study the mechanism of this tissue difference in siR-
NA-silencing efﬁciency, we ﬁrst analyzed the expression levels of
shRNA and siRNA with the probe to the guide strand of siRNA,
and compared them to the expression level of the target mRNA
in each tissue. The 54 mer shRNA was not detected in any tissue
(data not shown), indicating that processing of shRNA by Dicer is
excellent and not different among tissues. The processed guide
strand of 21 mer siRNA was observed much more in the cerebrum
than in the liver and skeletal muscle (Fig. 4A and B). As shown in
Fig. 2C, in contrast, SOD1 mRNA level was relatively lower in the
cerebrum in comparison with that in the liver. These clearly indi-WT TG WT TG WT TG
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cerebrum and liver on Western blot analysis.cate that relative ratio of the processed siRNA to the target mRNA
in tissues does not explain the difference in siRNA-silencing
efﬁciency.
Next, to examine whether the guide strand of siRNA properly
located in the cells, we performed Northern blot analysis after sub-
cellular fractionation of the tissue homogenates. Most of the guide
strand was detected in the cytoplasmic fraction in both of the cere-
brum and liver (Fig. 4C). These results show that the shRNA is sim-
ilarly exported from the nucleus to the cytoplasm and that the
guide strand should be similarly processed in the cytoplasm in
the cerebrum and liver. These suggest that the slicer/RISC function,
siRNA-cleaving ability, was lower in the cerebrum than in the liver.
Therefore, we ﬁnally analyzed expression of Ago2 protein which is
considered to be the slicer in mammalian cells [17]. However, the
expression of Ago2 protein was not lower in the cerebrum
(Fig. 4D), which was previously reported [18,19]. These ﬁndings
suggest that the lower silencing efﬁciency in the cerebrum could
not be explained by Ago2 level. The exact molecular mechanismTotal Nucl Cyto Total Nucl Cyto
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Fig. 5. Endogenous microRNA pathway in the shRNA transgenic mice. (A) Endog-
enous levels of miRNAs, let-7a (upper) and miR-124a (middle), in the cerebrum on
Northern blot analysis. (B) Quantiﬁcation of N-ras and N-myc levels, which are
predicted as target genes of let-7a, in the cerebrum by quantitative RT-PCR (mean
and S.D., n = 3). (C) N-ras protein in the cerebrum on Western blot analysis.
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elucidated.
3.5. Endogenous miRNA pathway is not affected in the cerebrum of
shRNA transgenic mice
To analyze whether competition between shRNA and miRNA
occurred in the shRNA transgenic mice, we evaluated the expres-
sion levels of miRNAs and their target genes in the cerebrum of
shRNA transgenic mice. There was no remarkable change in levels
of let-7a and miR-124a on Northern blot analysis (Fig. 5A). Expres-
sion levels of N-ras and N-myc mRNAs, which were the predicted
target genes of let-7a [20,21], were not altered on quantitative
RT-PCR (Fig. 5B). Expression level of N-ras protein was not altered
on Western blot analysis (Fig. 5C). These results clearly indicate
that endogenous miRNA pathway is preserved in the shRNA trans-
genic mice.
The reproducibility of all results was conﬁrmed by at least two
experiments.
4. Discussion
We demonstrated the tissue difference in siRNA-silencing
efﬁciency in the anti-SOD1 shRNA transgenic mice, but could not
make clear the exact mechanism for the difference. However, the
silencing effects in the tissues were generally good (>80%), and
the anti-SOD1 shRNA transgenic mice could recapitulate the
phenotype of fatty liver and female infertility as seen in SOD1-null
mice [15,16].
Overexpression of shRNA from transgene did not induce
apparent adverse effect including inhibition of endogenous miRNA
pathway in our transgenic mice. It is of note that abundant shRNA/
siRNA exogenously delivered by adeno-associated virus (AAV)
vectors can cause drastic toxicity in the liver or brain possiblydue to oversaturation of endogenous miRNA pathway [9,22]. The
absence of the toxicity in the shRNA transgenic mice is probably
due to its lower expression, because such a tissue toxicity is depen-
dent on expression level of shRNA/siRNA [9,22]. Alternatively,
there might be a difference in the processing pathways between
shRNA expressed from transgene and that exogenously expressed
by viral vector.
In conclusion, even with tissue difference in siRNA-silencing
efﬁciency, endogenous miRNA pathway being well preserved, the
transgenic RNAi approach is considered to be a useful method for
analysis of gene function in vivo.
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